Company: XERI
Filing Date: 2025-02-14
Form Type: 10-Q
Source: 0001477932-25-001010
Chunk: 1

Company: XERIANT, INC.
Filing Date: 2025-02-14
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
,392   36,197 Total liabilities  8,966,076   9,325,459          Commitments and contingencies (Note 9)                 Stockholders' deficit        Series A Preferred stock, $0.00001 par value; 100,000,000 authorized; 3,500,000 designated; 682,216 and 705,895 shares issued and outstanding at December 31, 2024 and June 30, 2024, respectively  7   7 Series B Preferred stock, $0.00001 par value; 100,000,000 authorized; 1,000,000 designated; 1,000,000 issued and outstanding  10   10 Common stock, $0.00001 par value; 5,000,000,000 shares authorized; 606,379,671 and 524,853,304 shares issued and outstanding at December 31, 2024 and June 30, 2024, respectively  6,064   5,248 Common stock to be issued  97,900   51,950 Additional paid in capital  21,564,889   20,899,187 Accumulated deficit  (27,483,811)  (26,708,915)Total stockholders' deficit  (5,814,941)  (5,752,513)Non-controlling interest  (2,874,536)  (2,859,941)Total stockholders' deficit  (8,689,477)  (8,612,454)Total liabilities and stockholders' deficit $276,599  $713,005 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

 F-2Table of Contents

 XERIANT, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED   For the three months ended  For the six months ended   December 31,  December 31,   2024  2023  2024  2023 Operating expenses:            Consulting and advisory fees $36,137  $102,650  $125,120  $154,345 Related party consulting fees  128,000   77,000